Anavex Life Sciences Corp (AVXL)

[Steady_T]

There are other factors that are involved that are not included in your analysis. There is unmet need which may mitigate the only one P3 trial issue. There is also the very low SOC which may have the AD results viewed more favorably than your analysis considers. There is the relative safety of 2-73 to be considered. One can argue that a safe but ineffective drug still doesn't get approved. However given that the approved MABS have marginal efficacy and significant safety issues, it is hard to predict where 2-73 will come out in that evaluation by the EMA.

Then there is the financial burden issues of AD. The EU seems to consider that with the rejection on the MABS for a cost benefit ratio consideration. 2-73 looks to be considerably cheaper that treatment with the MABS.
The points you make are legit. I'm suggesting there may be other considerations that are not included in your analysis.

We shall see what the EMA decides in due course.